Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.50 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.50 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.50 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | F11 | P03951 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | HMGCR | P04035 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16684305 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL2257134 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL14571284 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL5379160 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL18574064 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL14602169 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL10062436 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL21007943 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL20693186 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL14477068 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1172369-B1 | Synthesis of 2-deoxy-2-fluoro-arabinose derivates | AIR PROD & CHEM (US) | 2010-09-22 | — | — | EP | claimed |
| WO-2008069451-A1 | IMPROVED PROCESS FOR THE PREPARATION OF CLEVUDINE AS ANTI-HBV AGENT | BUKWANG PHARM CO., LTD. (KR) | 2008-06-12 | — | — | WO | claimed |
| US-6462191-B1 | DEOXOFLUORINATION OF FURANOSE; HEATING | AIR PRODUCTS AND CHEMICALS, INC. | 2002-10-08 | — | — | US | claimed |
| EP-1172369-A1 | Synthesis of 2-deoxy-2-fluoro-arabinose derivates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2002-01-16 | — | — | EP | claimed |
| WO-2022256490-A9 | IMPROVED SYNTHESIS OF PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | Antios Therapeutics, Inc. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20120309705-A1 | NOVEL 3'-DEOXY-3'-METHYLIDENE-BETA-L-NUCLEOSIDES | NOVADEX PHARMACEUTICALS AB (SE) | 2012-12-06 | — | — | US | disclosed |
| US-7511027-B2 | Method of treating hepatitis delta virus infection | GEORGETOWN UNIVERSITY (US) | 2009-03-31 | — | — | US | disclosed |
| WO-2008069451-A1 | IMPROVED PROCESS FOR THE PREPARATION OF CLEVUDINE AS ANTI-HBV AGENT | BUKWANG PHARM CO., LTD. (KR) | 2008-06-12 | — | — | WO | disclosed |
| EP-1284720-B1 | L-FMAU FOR THE TREATMENT OF HEPATITIS DELTA VIRAL INFECTION | UNIV GEORGETOWN (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1283211-B1 | L-Nucleosides for the treatment of hepatitis B-virus and Epstein-barr virus | UNIV GEORGIA RES FOUND (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1634888-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1600452-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2001034618-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | PHARMASSET LIMITED (US) | 2001-05-17 | — | — | WO | disclosed |
| US-5808040-A | VIRICIDES | YALE UNIVERSITY (US) | 1998-09-15 | — | — | US | disclosed |
| US-5753789-A | Oligonucleotides containing L-nucleosides | YALE UNIVERSITY (US) | 1998-05-19 | — | — | US | disclosed |
| US-5587362-A | VIRICIDES FOR HEPATITIS VIRUS AND EPSTEIN-BAR VIRUS | UNIV. OF GA RESEARCH FOUNDATION (US) | 1996-12-24 | — | — | US | disclosed |
| EP-0748330-A1 | L-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B-VIRUS AND EPSTEIN-BAR VIRUS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1996-12-18 | — | — | EP | disclosed |
| US-5567688-A | ADMINISTERING SPECIFIED ENANTIOMORPH TO HUMAN INFECTED WITH HEPATITIS B VIRUS | UNIV. OF GA RESEARCH FOUNDATION (US) | 1996-10-22 | — | — | US | disclosed |
| US-5565438-A | L-nucleosides for the treatment of epstein-bar virus | UNIVERSITY OF GA RESEARCH FOUNDATION (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1995020595-A1 | L-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B-VIRUS AND EPSTEIN-BAR VIRUS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1995-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309705-A1 | NOVEL 3'-DEOXY-3'-METHYLIDENE-BETA-L-NUCLEOSIDES | ENTPD5, MTAP, SLC29A1 | PTPN1 4437/4885USP2 4234/4885POLB 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.